Driehaus Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$246M Sell
845,773
-113,275
-12% -$37.5M 1.71% 4
2026
Q2
$321M Buy
959,048
+9,823
+1% +$3.11M 1.86% 3
2026
Q1
$306M Buy
949,225
+16,164
+2% +$5M 2.25% 2
2025
Q4
$275M Buy
933,061
+432,510
+86% +$80.5M 1.87% 3
2025
Q3
$26.5M Sell
500,551
-30,437
-6% -$1.48M 0.19% 175
2025
Q2
$22.3M Buy
530,988
+49,390
+10% +$1.88M 0.18% 165
2025
Q1
$18.2M Buy
481,598
+316,686
+192% +$19.8M 0.18% 171
2024
Q4
$12.7M Sell
164,912
-1,144
-0.7% -$82.8K 0.1% 220
2024
Q3
$9.6M Sell
166,056
-98,632
-37% -$5.33M 0.08% 235
2024
Q2
$10.9M Sell
264,688
-1,808
-0.7% -$85.4K 0.11% 208
2024
Q1
$16.3M Buy
+266,496
New +$12M 0.16% 186

Other funds holding PRAX

Driehaus Capital Management's PRAX Position: Q3 2026 in Review

Driehaus Capital Management reduced its Praxis Precision Medicines (PRAX) stake by 12% in Q3 2026, selling an estimated $37.5M and leaving 845,773 shares worth $246M. The position accounts for 1.71% of the portfolio, ranked #4.

Driehaus Capital Management first reported a position in PRAX in Q1 2024 and has held it in 11 quarters since. The position peaked at $321M in Q2 2026. 281 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.

  • Driehaus Capital Management held 845,773 shares of Praxis Precision Medicines worth $246M as of Q3 2026.
  • Driehaus Capital Management sold 113,275 Praxis Precision Medicines shares in Q3 2026, an estimated $37.5M.
  • Praxis Precision Medicines made up 1.71% of Driehaus Capital Management's portfolio in Q3 2026, its #4 holding.
  • Driehaus Capital Management first reported a position in Praxis Precision Medicines in Q1 2024 and has held it in 11 quarters since.
  • Driehaus Capital Management's Praxis Precision Medicines position peaked at $321M in Q2 2026.
  • 281 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.

Based on Driehaus Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.